David  Bharucha net worth and biography

David Bharucha Biography and Net Worth

Chief Medical Officer of Milestone Pharmaceuticals

Dr. Bharucha joined Milestone Pharmaceuticals as Chief Medical Officer in February 2022. He is a cardiac electrophysiologist who brings considerable global drug-development and clinical experience in cardiovascular and multiple other therapeutic areas. Prior to Milestone, Dr. Bharucha served as Vice President, R&D at AbbVie and Allergan where he headed multiple sections including leadership of innovative programs in cardiology, cardiac surgery, arrhythmia, and hypertension. Dr. Bharucha has led work resulting in regulatory approvals including those impacting product label expansion in and outside the U.S. He has held R&D governance board positions including responsibilities spanning early- to late-development and post-approval life-cycle management; led teams in the anti-infectives, women’s health, and urology spaces; and represented R&D functions of these prior companies in consortium- and government-partnered trials, in business development actions, and in collaboration with commercial partners. Prior to his most recent positions, he held roles of increasing responsibility at Forest Laboratories and Actavis PLC. Prior to joining industry R&D, Dr. Bharucha was on faculty at Mt. Sinai School of Medicine, NYC, and Jefferson Medical University, Philadelphia (Mainline Health), and was a practicing cardiac electrophysiologist in those organizations.

Dr. Bharucha’s training included fellowships (cardiology and cardiac electrophysiology) at the Massachusetts General Hospital, Harvard Medical School; residency (internal medicine) at the Hospital of the University of Pennsylvania; an MD and PhD (Biochemistry & Molecular Biology) from the University of Chicago; and a BA (Biology) from Haverford College.

What is David Bharucha's net worth?

The estimated net worth of David Bharucha is at least $115.18 thousand as of December 15th, 2025. Dr. Bharucha owns 91,993 shares of Milestone Pharmaceuticals stock worth more than $115,175 as of August 10th. This net worth approximation does not reflect any other investments that Dr. Bharucha may own. Learn More about David Bharucha's net worth.

How do I contact David Bharucha?

The corporate mailing address for Dr. Bharucha and other Milestone Pharmaceuticals executives is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. Milestone Pharmaceuticals can also be reached via phone at (514) 336-0444 and via email at [email protected]. Learn More on David Bharucha's contact information.

Has David Bharucha been buying or selling shares of Milestone Pharmaceuticals?

David Bharucha has not been actively trading shares of Milestone Pharmaceuticals during the past quarter. Most recently, David Bharucha sold 12,245 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a transaction totalling $23,632.85. Following the completion of the sale, the insider now directly owns 99,848 shares of the company's stock, valued at $192,706.64. Learn More on David Bharucha's trading history.

Are insiders buying or selling shares of Milestone Pharmaceuticals?

During the last twelve months, insiders at the sold shares 11 times. They sold a total of 452,827 shares worth more than $1,017,948.37. The most recent insider tranaction occured on April, 16th when CEO Joseph Oliveto sold 36,500 shares worth more than $82,490.00. Insiders at Milestone Pharmaceuticals own 5.0% of the company. Learn More about insider trades at Milestone Pharmaceuticals.

Information on this page was last updated on 4/16/2026.

David Bharucha Insider Trading History at Milestone Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/26/2026Sell12,245$1.93$23,632.8599,848View SEC Filing Icon  
12/15/2025Sell58,007$2.32$134,576.2491,993View SEC Filing Icon  
12/5/2022Buy7,000$4.69$32,830.0010,000View SEC Filing Icon  
12/1/2022Buy3,000$4.86$14,580.003,000View SEC Filing Icon  
See Full Table

David Bharucha Buying and Selling Activity at Milestone Pharmaceuticals

This chart shows David Bharucha's buying and selling at Milestone Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Milestone Pharmaceuticals Company Overview

Milestone Pharmaceuticals logo
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Read More

Today's Range

Now: $1.27
Low: $1.20
High: $1.28

50 Day Range

MA: $1.24
Low: $1.04
High: $1.36

2 Week Range

Now: $1.27
Low: $1.00
High: $3.06

Volume

1,342,655 shs

Average Volume

1,872,258 shs

Market Capitalization

$157.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98